Breaking News Instant updates and real-time market news.

Rockwell Medical announced that the Triferic Phase 1 Healthy Volunteer Intravenous Pharmacokinetic Study has been published in the Journal of Clinical Pharmacology. Triferic is the company's new and innovative FDA approved anemia therapy indicated to replace iron-and maintain hemoglobin in chronic kidney disease patients receiving hemodialysis.

RMTIRockwell Medical

$6.74

0.04 (0.60%)

03/01/16

STFL

03/01/16DOWNGRADESTFLHold

Rockwell Medical downgraded to Hold from Buy at Stifel

03/01/16

CHLM

03/01/16DOWNGRADETarget $7CHLMHold

Rockwell Medical downgraded to Hold from Buy at Craig-Hallum

Craig-Hallum analyst Charles Haff downgraded Rockwell Medical to Hold and lowered his price target to $7 from $14 on shares following weak Q4 results and the commercial strategy change for Triferic.

03/01/16

STFL

03/01/16DOWNGRADESTFLHold

Rockwell Medical downgraded at Stifel

As noted earlier, Stifel downgraded Rockwell Medical to Hold from Buy. The firm cited weak Q4 sales of the company's Triferic treatment as the reason for the downgrade.

08/19/16

BTIG

08/19/16INITIATIONTarget $12BTIGBuy

Rockwell Medical initiated with a Buy at BTIG

BTIG analyst Ling Wang initiated Rockwell Medical with a Buy and $12 price target saying its lead asset, Triferic, has the potential to replace IV iron in hemodialysis patients.